As weight-loss drugs are gaining popularity among Indian diabetes and obesity stricken patients in India, new research highlights rare but serious eye risks linked to the blockbuster GLP-1 medications ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these findings, a clear link has yet to be established, and much of the evidence remains ...

New research links two widely used diabetes drugs, semaglutide or tirzepatide, to a rare but potentially vision-threatening eye condition, raising questions about drug-specific risks and the need ...

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

A study published in JAMA Network, by the Case Western Reserve University examined about 15,11,637 eligible participants with ...

GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that regulate blood sugar, appetite, and digestion. GLP-1 (glucagon-like ...

Overview - As demand for GLP-1 drugs continues to skyrocket, federal and state agencies are turning their attention to the GLP-1 ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

The lawsuit, which was filed in U.S. District Court in New Jersey by a single investor, Eric Barta, is a class action on ...